Another jury says yes. Does baby powder cause
Another jury says yes. Does baby powder cause cancer?
TRENTON, N.J. – For the third time, Johnson & Johnson has been hit with a multimillion-dollar jury verdict over whether the talc in its iconic baby powder causes ovarian cancer when applied regularly for feminine hygiene .
Late Thursday, a St. Louis jury awarded $70.1 million to Deborah Giannecchini of Modesto, California, who was diagnosed with advanced ovarian cancer in 2012. Giannecchini, then 59, said she had used Johnson's Baby Powder for more than 40 years to keep her genital area dry, as many women do. She blamed it for her cancer and accused J&J of negligence.
Two other jury trials in St. Louis reached similar outcomes earlier this year, awarding the plaintiffs $72 million and $55 million.
But in J&J's home state of New Jersey a judge recently threw out two other cases, ruling there wasn't reliable evidence talc causes ovarian cancer, a relatively rare disease.
Johnson & Johnson says its product is safe, and it is appealing all three losses. And investors don't seem worried that J&J is in financial trouble, even though the company faces an estimated 2,000 similar lawsuits. J&J shares fell 0.3 percent Friday, about the same as the broader stock market, to close at $115.33.
The next trial is set to start in January, also in St. Louis.
Here's what experts say about talc and cancer.
WHAT IS TALC?
Talc is a mineral that is mined from deposits around the world, including the U.S. The softest of minerals, it's crushed into a white powder. It's been widely used in cosmetics and other personal care products to absorb moisture since at least 1894, when Johnson & Johnson's Baby Powder was launched. But it's mainly used in a variety of other products, including paint and plastics.
DOES IT CAUSE OVARIAN CANCER?
Like many questions in science, there's no definitive answer. Finding the cause of cancer is difficult. It would be unethical to do the best kind of study, asking a group of women to use talcum powder on their genitals and wait to see if it causes cancer, while comparing them to a group who didn't use it.
While ovarian cancer is often fatal, it's relatively rare. It accounts for only about 22,000 of the 1.7 million new cases of cancer expected to be diagnosed in the United States this year.
Factors that are known to increase a women's risk of ovarian cancer include age, obesity, use of estrogen therapy after menopause, not having any children, certain genetic mutations and personal or family history of breast or ovarian cancer.
WHAT RESEARCH SHOWS
The biggest studies have found no link between talcum powder applied to the genitals and ovarian cancer. But about two dozen smaller studies over three decades have mostly found a modest connection — a 20 percent to 40 percent increased risk among talc users.
However, that doesn't mean talc causes cancer. Several factors make that unlikely, and there's no proof talc, which doesn't interact with chemicals or cells, can travel up the reproductive tract, enter the ovaries and then trigger cancer.
One large study published in June that followed 51,000 sisters of breast cancer patients found genital talc users had a reduced risk of ovarian cancer, 27 percent lower than in nonusers. An analysis of two huge, long-running U.S. studies, the Women's Health Initiative and the Nurses' Health Study, showed no increased risk of ovarian cancer in talc users.
WHAT EXPERTS SAY
If there were a true link, Dr. Hal C. Lawrence III says large studies that tracked women's health for years would have verified results of the smaller ones.
"Lord knows, with the amount of powder that's been applied to babies' bottoms, we would've seen something," if talc caused cancer, said Lawrence, vice president of the American College of Obstetrics and Gynecology.
The National Cancer Institute's Dr. Nicolas Wentzensen says the federal agency's position is that there's not a clear connection.
"It is very hard to establish causal relationships," he said, adding, "A lot of ovarian cancers occur in women who have never used talc, and many women have used talc and not gotten ovarian cancer."
Research director Elizabeth Ward of the American Cancer Society says it is unusual to have so much discrepancy between studies. "The risk for any individual woman, if there is one, is probably very small," Ward said.
Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP
Scroll down for more posts ▼
Top 10 Most Recent News Articles
MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...
Continue Reading
China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...
Continue Reading
NatGold Digital's sudden decision to yank its NATG token off MEXC Global reeks of regulatory urgency. With the U.S. Treasury clamping down on fund transfers wrapping up MEXC in their action against Russian laundering, NatGold didn't wait for the ink to dry on that order. They’re off the exchange posthaste. A bit of foresight or sheer necessity? Well, it's got the market...
Continue Reading
Challenging Longstanding Beliefs Today’s news from the heart research front might set a few cardiology heads spinning. We’ve got big-time findings out of the ISCHEMIA-EXTEND study, throwing more weight on the evidence pile that early invasive heart procedures for patients with stable coronary artery disease don’t actually extend your life. Managing care with a blend...
Continue Reading
Here's the scoop: an Off-Broadway production just did something many big hitters can't pull off. 'DUST,' a show crafted like a love letter to the American West, managed to rustle up $30,000 for young adults grappled with autism. Partnering with no less than Yale's Cultural Autism Studies and the Ed Asner Family Center, this effort hit the mark in more ways than one. An...
Continue Reading
Race to Remember: Monumental Breakthroughs In the chilly November air of Indianapolis, the 2026 CNO Financial Indianapolis Monumental Marathon wasn't just another tick on the calendar—this was a banner day for running. With record-breaking performances across every distance, we saw what happens when a community of athletes, sponsors, and volunteers hits a perfect...
Continue Reading
The Changing Landscape of Global Media An event of this magnitude doesn't just pop up every day like a stock ticker on Wall Street. This year's 7th World Media Summit in Beijing is where nearly 500 bigwigs from all corners of the media landscape are converging. It's not about trading stocks or hitting quarterly numbers—it's about shaping how stories get told in an era...
Continue Reading
Sizing Up the Installation Options Slapping a fireplace into a home sounds more like a pipe dream than a practical project for most folks. But according to fireplace whiz Jimmy Smith down in North Charleston, the times are a-changin'. These days, with advances in technology, homeowners can actually pull it off without collapsing their living room walls. Nitty-Gritty:...
Continue Reading
Patient-Centric Take on Sjögren's Disease Johnson & Johnson has dropped fresh Phase 2 results on nipocalimab, reminding everyone they're at the helm of reshaping treatments for Sjögren's disease (SjD). A condition leaving about four million folks craving better days, in multiple ways, shines a light on what's gripping patients the hardest. It's hard not to sit up and...
Continue Reading
A New Chapter for JOYEE N01 There's a moment in every company's life when it either steps boldly into the future or stumbles back into obscurity. For FAW Bestune, October 28, 2026, was one of those defining moments. On this day, they launched global mass production of the JOYEE N01 in Yancheng, China. And boy, did they pull out all the stops—you don't see this kind of...
Continue Reading
Top 5 Most Recently Viewed Articles
NexGen Hyperbaric Partners with Philadelphia Flyers NexGen Hyperbaric is excited to announce a new collaboration with the Philadelphia Flyers, becoming the first franchise in the NHL to adopt hyperbaric oxygen therapy (HBOT) into their wellness strategy. This partnership aims to enhance the health and performance of both current athletes and former players, showcasing a...
Continue Reading
The US Dollar Gains Traction The US Dollar has seen significant gains lately, buoyed by rising Treasury yields that indicate a shift in market dynamics. As speculation continued about the future of the Federal Reserve Chair, the Dollar strengthened against various currencies. This month, the Dollar has been on a rally, indicating a robust performance against major...
Continue Reading
Eve Air Mobility's Significant Equity Raise Eve Air Mobility (NYSE: EVEX) has recently made headlines with its ambitious plan to raise $230 million through a registered direct offering. This initiative is designed to enhance the company’s efforts in the Urban Air Mobility (UAM) sector, showcasing their commitment to advancing eVTOL aircraft technology. Subscription...
Continue Reading
Market Reaction to PDD Holdings Recently, PDD Holdings (NASDAQ: PDD) faced some market pressure, even though there was no significant news from the company. Following their earnings release, several analysts lowered their price targets, which triggered a noticeable sell-off in the market. PDD's American depositary receipts (ADRs) dropped by more than 4%, in stark contrast...
Continue Reading
Progenity Inc's Stock Hits Record Low In a year fraught with challenges, Progenity Inc has found itself grappling with a steep decline in stock prices, reaching a worrying 52-week low of $0.47. The biotech company, noted for its innovative health solutions, has seen its stock value plunge by an alarming 77.71% over the year. Investors have been anxious as the company...
Continue Reading